IMMX
NASDAQ · Biotechnology
Immix Biopharma Inc
$9.11
-0.57 (-5.89%)
Open$9.60
Previous Close$9.68
Day High$10.05
Day Low$8.93
52W High$8.97
52W Low$1.34
Volume—
Avg Volume547.6K
Market Cap452.24M
P/E Ratio—
EPS$-0.77
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+31.5% upside
Current
$9.11
$9.11
Target
$11.98
$11.98
$7.05
$11.98 avg
$14.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 163.82M | 157.27M | 158.27M |
| Net Income | -44,702,535 | -44,556,024 | -43,506,106 |
| Profit Margin | -27.3% | -28.3% | -27.5% |
| EBITDA | -45,867,623 | -43,115,764 | -48,402,369 |
| Free Cash Flow | -22,695,190 | -23,234,474 | -24,663,069 |
| Rev Growth | +3.0% | +15.0% | +13.1% |
| Debt/Equity | 0.40 | 0.42 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |